Opinion|Videos|December 5, 2025
PCSK9 Inhibitor Underuse
Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.
Advertisement
Episodes in this series
Panelists discuss how PCSK9 inhibitors remain underutilized despite their strong efficacy and safety record. The main barriers are cost, prior authorization requirements, and patient hesitancy with injectable formats.
They note that even eligible high-risk patients often abandon therapy due to administrative complexity or affordability.
Panelists call for streamlined access pathways and education to ensure these life-saving agents reach appropriate patients.
Advertisement
Related to this article
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
3
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5